Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Completed Phase 3 Interventional

Memory Impairment Study (Mild Cognitive Impairment Study)

NCT00000173
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donepezil, Vitamin E
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
63
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

NCT01595646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD

NCT05004688
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Moderate Dementia, Alzheimer Disease
Interventions
Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
Biological
Lead sponsor
Steven E Arnold, MD
Other
Eligibility
55 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2025 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

NCT05456503
View directory record Official record
Conditions
Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
Interventions
[18F]-PI-2620
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Active, not recruiting Early Phase 1 Interventional

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

NCT04075435
View directory record Official record
Conditions
Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
high CBD/low THC sublingual solution
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Comparative Effectiveness Dementia & Alzheimer's Registry

NCT03687710
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Multidomain precision medicine intervention
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)

NCT07127133
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Dementia
Interventions
Insole and ankle device
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
55 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Person-Environment Fit for Persons With Dementia

NCT05722743
View directory record Official record
Conditions
Dementia Alzheimers, Alzheimer Disease
Interventions
Harmony at HOME, National Institute on Aging Program
Behavioral
Lead sponsor
Elizabeth K Rhodus
Other
Eligibility
21 Years to 99 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 13, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

NCT03274817
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

NCT01320527
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nutriceutical formulation, Placebo
Dietary Supplement · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional Results available

Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints

NCT00597376
View directory record Official record
Conditions
Subjective Memory Loss in Older Persons
Interventions
Cerefolin NAC (a medical food), Cerefolin NAC placebo
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2013 · Synced Oct 13, 2026, 6:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Evaluation and Follow-up of Individuals With Memory Disorder

NCT00001480
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Healthy, Memory Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms

NCT06930560
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Hearing Loss, Cognitive Impairment
Interventions
HEARS-NPS device, HEARS-NPS program
Device · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 13, 2026, 6:41 PM EDT
Not listed No phase listed Observational

Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey

NCT06025877
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Interventions
PrecivityAD2(TM) blood test
Other
Lead sponsor
C2N Diagnostics
Industry
Eligibility
55 Years and older
Enrollment
400 participants
Timeline
2023 – 2025
U.S. locations
9
States / cities
San Francisco, California • Santa Monica, California • Park Ridge, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Wake Forest Alzheimer's Disease Clinical Core

NCT03140865
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2031
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional

Music Therapy Experiences in Patients With Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

NCT04666077
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Home-based MT through Supervised, Supported Singing (H3S), Individualized Music Therapy (IMT), Attention Control (AtCon)
Behavioral · Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional

Using Light Therapy for Mild Cognitive Impairment

NCT07651787
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Amyloid Pathology
Interventions
Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation, Sham Vielight Neuro RX-Duo device -Sham transcranial photobiomodulation
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
55 Years to 95 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

NCT05661084
View directory record Official record
Conditions
Dementia, Memory Loss, Alzheimer Disease, Executive Dysfunction, Mobility Limitation
Interventions
Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham), Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)
Device
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SHARE(D) Stage II: Alzheimer's Risk Disclosure Protocol Piloting

NCT04309500
View directory record Official record
Conditions
Mild Cognitive Impairment, Healthy Aging
Interventions
Personalized DAT Risk Disclosure Protocol
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 13, 2026, 6:41 PM EDT
Terminated Phase 3 Interventional Results available

A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

NCT00998764
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bapineuzumab 0.5 mg/kg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
51 Years to 90 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
66
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting No phase listed Observational

F 18 T807 Tau PET Imaging of Alzheimer's Disease

NCT02414347
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Recruiting Not applicable Interventional

Phase 2 - Rhythmic Light Therapy for Alzheimer's Disease Patients

NCT05016219
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Circadian-Effective Light, Rhythmic Light, Placebo Light, Placebo Rhythmic Light
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Menands, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 13, 2026, 6:41 PM EDT
Completed Phase 2Phase 3 Interventional

Enhanced CBTi for Older Adult Sleep and Cognition

NCT05015803
View directory record Official record
Conditions
Insomnia, Alzheimers Disease Related Dementias
Interventions
CBTi with Application, CBTi, Sleep Hygiene Education
Combination Product · Behavioral
Lead sponsor
Penn State University
Other
Eligibility
60 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 13, 2026, 6:41 PM EDT
Completed No phase listed Observational

Clinical Evaluation of Florbetapir in Primary Progressive Aphasia

NCT04726527
View directory record Official record
Conditions
Primary Progressive Aphasia, Alzheimer Disease, Dementia
Interventions
Florbetapir F 18, Positron Emission Tomography
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
48 participants
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 13, 2026, 6:41 PM EDT